Fintel reports that on January 22, 2026, Oppenheimer initiated coverage of Coherus Oncology (NasdaqGM:CHRS) with a Outperform ...

Oncology bedrock remains vital as the TNM system evolves to ensure precise, equitable cancer staging worldwide for clinicians and patients.

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and ...

Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.

The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by ...

The most striking finding in recent oncological research is the significant gain in survival rates for cancers previously ...

By Arasu Kannagi Basil Jan 7 (Reuters) - Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, signaling ...

The dyad model fosters collaboration between academic specialists and community oncologists, ensuring seamless patient care ...

SAN FRANCISCO -- An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended ...

Investing.com -- Coherus Oncology (NASDAQ:CHRS) stock surged 35% on Friday after Oppenheimer initiated coverage with an Outperform rating and a $10 price target, representing substantial upside from ...

Tierney says that if there’s one category oncology dietitians consistently encourage people to eat more of, it’s non-starchy ...

The 12,500-square-foot wing will be on the first floor of the hospital’s Diamond Head Tower and nearly triple the size of the ...